« Back
Expression of MSH2 in Head and Neck Lymphomas  (A Study Utilizing Immunohistochemistry and Real-time Polymerase Chain Reaction)
Poster Title: Expression of MSH2 in Head and Neck Lymphomas (A Study Utilizing Immunohistochemistry and Real-time Polymerase Chain Reaction)
Submitted on 11 Feb 2020
Author(s): Safa Fathi Abdel-Ghani, Rehab Fawzi Kasem , Dina Soliman Khater
Affiliations: 1&3 Professor of Oral and Maxillofacial Pathology, Faculty of Dentistry, Cairo University. 2Professor of Oral and Maxillofacial Pathology, Faculty of Dentistry, Cairo University and the Head of the Oral Pathology Department, Faculty of Dentistry, October University of Modern Science and Arts (MSA).
This poster was presented at the second annual scientific day of the oral and maxillofacial pathology department, Cairo University
Poster Views: 478
View poster »

Poster Information
Abstract: ABSTRACT
Background and Objective: Lymphomas are malignant neoplastic proliferations that cause major health problems worldwide. However, the precise pathogenesis and underlying molecular mechanisms of both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) are not fully elucidated. Accordingly, the aim of the present study was to detect the expression of MSH2 at the gene and protein levels in HL and NHL of the head and neck. Materials and Methods: Expression of MSH2 on gene and protein levels were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry respectively. A total of 26 archival specimens were selected including normal lymph nodes (6 cases) which were used as a control group, lingual tonsils with lymphoid hyperplasia (6 cases) and 14 cases of lymphomas of submandibular and sublingual lymph nodes. Lymphomas were classified into of HL (6 cases of mixed cellularity type) and NHL (8 cases of diffuse B cell lymphoma). Results: Lower expression of MSH2 in NHL than HL was also observed. Moreover, a positive correlation was detected between the expression of MSH2 protein and its mRNA among the examined groups. Conclusion: Lower expression of MSH2 in NHL than that of HL suggested a more aggressive behavior and poor prognosis in this lesion. The reduced expression of MSH2 could be considered as a molecular biomarker for loss of MMR activities and it might serve as a prognostic biomarker for head and neck lymphomas.

Summary: In Egypt, lymphomas have represented an important oncologic problem. Studies have proposed that mutations in MSH2, could be one of the critical genes that underlie a novel pathway of tumourogenesisi for some cancers. this study concluded that reduced expression of MSH2 in malignant lymphocytes could be used as an aid in prediction of prognosis of such lesions. Moreover, it might be used as a potential diagnostic marker to assess the risk of malignant transformation in lymphoid tissues.  
References: Barnetson, R.A., A. Tenesa, S.M. Farrington, I.D. Nicholl and R. Cetnarskyj et al., 2006. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med., 354: 2751-2763.
CrossRef | Direct Link |

Cooper, W.A., M.R.J. Kohonen‐Corish, C. Chan, S.Y. Kwun and B. McCaughan et al., 2008. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non‐small‐cell lung cancer and precursor lesions. Histopathology, 52: 613-622.
CrossRef | Direct Link |

El-Naggar, A.K., J.K.C. Chan, J.R. Grandis, T. Takata and P.J. Slootweg, 2017. WHO Classification of Head and Neck Tumours. 4th Edn., International Agency for Research on Cancer, Lyon, France, ISBN: 9789283224389, Pages: 347.

Goteri, G., G. Lucarini, A. Zizzi, A. Costagliola and F. Giantomassi et al., 2011. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas.
Report abuse »
Creative Commons